Welcome to the Neurology News Network, my name is Louie Pasculli and here’s a look at some of the top stories in Neurology.

Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.

Assessing Long-Term Disease Control With Nipocalimab in Pediatric Generalized Myasthenia Gravis: Jonathan Strober, MD In a ...

Amanda L. Piquet, MD, reviews 1-year KYSA-8 findings, highlighting sustained clinical improvements and safety outcomes with ...

QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower ...

Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker ...

Brain Chat with the Nerdy Neurologist is a podcast hosted by Mitzi Joi Williams, MD that brings together clinicians, experts, and people with lived experience to make complex neurologic and health ...

Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, ...

IJMSC editor-in-chief, François Bethoux, MD, and colleagues cover idea generation, poster conversion, literature reviews, and ...

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed open-label extension data ...

The president and founder of the Stuttering Treatment and Research Society (STARS) discussed highlights from the society's ...

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T ...